Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Enveric’s preclinical PK studies of EB-003 show oral bioavailability without hallucinogenic effects

Enveric Biosciences (NASDAQ:ENVB) announced the completion of preclinical pharmacokinetic (PK) studies of EB-003, which support its oral bioavailability and targeted non-hallucinogenic profile. EB-003 is a potential...

November 25, 2024

Developments

BioLineRx enters license agreement with Ayrmid for APHEXDA

BioLineRx (NASDAQ:BLRX; TASE:BLRX) and Ayrmid, the parent company of Gamida Cell, announced they have entered into a licensing agreement for motixafortide, commercially marketed in the U.S. as BioLineRx’s APHEXDA. The...

November 22, 2024

Developments

Rallybio launches Phase II trial of RLYB212 for FNAIT in pregnancy

Rallybio (NASDAQ:RLYB) announced the commencement of an open-label Phase II trial of RLYB212 in pregnant women at high-risk of HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT). FNAIT is...

November 22, 2024

Developments

Perimeter’s B-Series OCT with ImgAssist AI demonstrates super-superiority compared to standard-of-care in breast cancer surgery pivotal clinical trial

Perimeter Medical Imaging AI (TSX-V:PINK) (OTC:PYNKF) announced positive topline results from the pivotal study designed to support its planned FDA PMA submission for approval to market its next-generation Perimeter B...

November 20, 2024

Executive Moves

MOBILion launches proteomics advisory board

Closely-held MOBILion Systems announced the formation of a proteomics advisory board to provide strategic guidance as the company advances the development of its next-generation high-resolution mass spectrometry...

November 20, 2024

Developments

Neurizon reports positive results from preclinical study of NUZ-001 in ALS

Neurizon Therapeutics (ASX: NUZ & NUZOA) announced positive results from a preclinical study of its lead candidate, NUZ-001, in amyotrophic lateral sclerosis (ALS). The company states that NUZ-001 reduces the...

November 19, 2024

Developments

Adverum announces positive 52-week LUNA results and four-year OPTIC data

Adverum Biotechnologies (NASDAQ:ADVM) announced topline 52-week results from its LUNA Phase 2 trial, new four-year long-term follow-up data from its OPTIC study, and key design elements for its pivotal program. Both the...

November 18, 2024

Developments

Therma Bright to spin off consumer product portfolio creating new company

Therma Bright (TSXV:THRM; QTCQB:TBRIF) announced plans to spin off its consumer product portfolio into a separate publicly traded company during the first half of 2025. The spin-off transaction will be subject to...

November 18, 2024

Executive Moves

MindMed names Gregg Pratt as chief regulatory and quality assurance officer

MindMed (NASDAQ:MNMD) has appointed Gregg Pratt, Ph.D., as chief regulatory and quality assurance officer. Dr. Pratt will oversee the company’s regulatory and quality functions, as well as its product registration...

November 18, 2024

Developments

AC Immune announces positive interim results from study of ACI-7104.056 in Parkinson’s

AC Immune (NASDAQ:ACIU) announced positive interim safety and immunogenicity data from its Phase 2 VacSYn clinical trial, evaluating ACI-7104.056 as a treatment for patients with early Parkinson’s disease. The company...

November 15, 2024

Executive Moves

Opthea names Kathy Connell to BOD

Opthea (ASX/NASDAQ:OPT) announced the appointment of Kathy Connell to its board of directors as a non-executive director. Ms. Connell brings extensive business development expertise across pharmaceutical, vaccine...

November 15, 2024

Developments

Moleculin amends protocol for Phase 3 trial of Annamycin for AML

Moleculin Biotech (NASDAQ:MBRX) announced it has amended the protocol with the FDA for its Phase 3 pivotal MIRACLE trial, evaluating Annamycin in combination with Cytarabine for treating patients with acute myeloid...

November 14, 2024

Enveric’s preclinical PK studies of EB-003 show oral bioavailability without hallucinogenic effects

BioLineRx enters license agreement with Ayrmid for APHEXDA

Rallybio launches Phase II trial of RLYB212 for FNAIT in pregnancy

Perimeter’s B-Series OCT with ImgAssist AI demonstrates super-superiority compared to standard-of-care in breast cancer surgery pivotal clinical trial

MOBILion launches proteomics advisory board

Neurizon reports positive results from preclinical study of NUZ-001 in ALS

Adverum announces positive 52-week LUNA results and four-year OPTIC data

Therma Bright to spin off consumer product portfolio creating new company

MindMed names Gregg Pratt as chief regulatory and quality assurance officer

AC Immune announces positive interim results from study of ACI-7104.056 in Parkinson’s

Opthea names Kathy Connell to BOD

Moleculin amends protocol for Phase 3 trial of Annamycin for AML

General

More